Overview: Hepatitis B Immunity Panel
Introduction: The Hepatitis B Immunity Panel is a diagnostic tool designed to assess hepatitis B immunity using serum samples. In India, hepatitis B affects ~40 million chronic carriers (~3 percent prevalence), with vaccination coverage improving but immunity assessment crucial for healthcare workers, high-risk groups, and post-exposure. High morbidity from under-testing in rural/low-SES populations, limited labs, delayed booster vaccination leading to breakthrough infection or chronicity. Per microbiology/immunology practices aligned with ICMR and National Viral Hepatitis Control Programme guidelines, the test employs immunoassay for HBsAb, HBcAb total, and HBsAg over 1-2 days with high accuracy, valuable for immunity status and exposure history. This diagnostic falls under immunity screening and targets vaccinated individuals, healthcare workers, or pre-pregnancy screening, addressing accurate detection to guide booster doses or antiviral prophylaxis. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise immunity assessment and reducing HBV transmission. Its serum-based approach ensures reliable serology.
Other Names: Hep B Imm Pnl.
FDA Status: FDA approved, CLIA certified for immunology/microbiology, compliant with 2025 standards.
Historical Milestone: HBV serology panel standard; in India, used in vaccination programs.
Purpose: The test assesses 3 parameters including HBsAb to guide hepatitis B immunity screening, detect protection/exposure, inform vaccination.
Test Parameters: 1. HBsAb, 2. HBcAb Total, 3. HBsAg.
Pretest Condition: No fasting required; patients should report vaccination history or risk.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on vaccination doses, exposure risk, liver symptoms.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected non-immunity including infection, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or recent vaccination can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive HBsAb (>10 mIU/mL) indicates immunity; HBsAg positive indicates infection, necessitating specialist input.
Specialist Consultation: Hepatologists or infectious disease specialists should be consulted for management.
Additional Supporting Tests: HBV DNA for confirmation.
Test Limitations: Does not assess cellular immunity; comprehensive approach required.
References: Indian Journal of Medical Microbiology 2024, HBV Studies India 2023.
